



BRITISH AMERICAN
TOBACCO

A large, abstract graphic on the left side of the slide. It features a thick, curved yellow brush stroke at the top, followed by a thick, curved dark blue brush stroke below it. The strokes have a textured, hand-painted appearance with some white highlights and shadows.

Regional Lung Deposition of Tobacco Smoke

John McAughey

A decorative footer consisting of several horizontal brush strokes. From top to bottom, there is a thick yellow bar, a thin white bar, a thin dark blue bar, and another thick yellow bar.

Background

- Deposition efficiency of mainstream tobacco smoke = 60-80% (Baker review of exhale capture studies)
- Deposition efficiency of ETS / aged sidestream smoke generally lower = 11 – 55% (exhale capture studies by Hiller, McAughey, Morawska)
- Deposition efficiencies generally greater than expected for measured diameter of particles
 - 180–860 nm (MS)
 - 100–300 nm (ETS/aged SS)
- Numerous mechanisms to explain enhanced MS deposition efficiency but no modelled fit
 - Coagulative growth
 - Hygroscopic growth
 - Cloud behaviour
- Review of radiotracer studies to offer insight to mechanisms with respect to smoke, smoking and inhalation behaviour
- Radiotracer studies conducted at the Harwell Laboratory, UK in the early to mid 1990s
- Conclusions are those of the author; not the sponsors

Physical Processes Controlling Smoke Deposition in Lung



- Smoke
 - Particle size
 - Chemical variation
 - solubility
 - vapour pressure
 - hygroscopicity
 - Physical variation
 - coagulation
 - ΔT & ΔH
 - cloud behaviour
 - evaporation
 - condensation
- Human
 - Breathing pattern
 - depth
 - flow
 - duration
 - Puff parameters
 - Physiology
 - disease
 - gender
 - laryngeal compression
 - ventilation asymmetry
 - intra- versus inter-individual behaviour

Radiotracers

Mainstream smoke

- ^{123}I -1-iodohexadecane ($\text{C}_{16}\text{H}_{33}\text{I}$)
- B.Pt. = 380°C (equivalent to average boiling pt. reported for tar condensate)
- Injected down length of tobacco rod in dichloromethane solution
- Decay half-time = 13.2 hours
- γ -emission of 160 keV

Pritchard et al, J. Aerosol Sci. **19**
715-724 (1988)

Aged & diluted SS

- ^{212}Pb
- Labelling *in situ* with pulse of ^{220}Rn (thoron) gas (from ^{228}Th) introduced into chamber with aged SS
- Rapid decay via ^{216}Po to ^{212}Pb
- Decay half-time = 10.6 hours
- γ -emission of 240 keV

Strong et al, J. Aerosol Sci. **25** 199-
207 (1994)

Study design

Mainstream smoke


- 14 male and 14 female smokers switching from 13_1.2_16 mg (8 weeks) to 10_1.2_9 mg product (26 weeks), in compensation study (PMWNF_NIC_CO)
- 2 cigarettes smoked naturally in chamber in pairs; active in ~50% of visits; regional deposition on 3 visits
- Multiple measurements of tar, nicotine, cotinine, CO, DCO, smoking parameters, inhalation parameters
- Average Committed Effective Dose Equivalent (CEDE) of 3.4 mSv (cf WHO, g-camera studies)

Aged & Diluted SS

- 9 non-smoking male volunteers
- Smoke aerosol generated in 180 litre chamber (~ 0.86 mg.m⁻³); sealed for thoron pulse; 15 minute decay period for ²¹²Pb
- Smoke diameter measured as 210 nm AMAD (Delron – GSD = 1.43) and 180 nm AMAD (QCM – GSD = 1.5)
- 6 minute controlled breathing with exhale capture
 - 6 x 1000 ml per min – nose
 - 6 x 1000 ml per min – mouth
 - 12 x 500 ml per min – mouth
- Average CEDE = 340 mSv

Differential Clearance

- Whole body counter
- Collimated NaI detectors
- Geometry : 1 x head, 2 x chest, 2 x stomach, 1 x leg
- Bronchial to pulmonary split by back-extrapolation of 2 curves
- Pulmonary behaviour limited by solubility of label
- No information on any slow bronchial clearance
- Regional deposition $\pm 1\%$ reproducible in individuals
- Dose of 1-5 Sv (deposition) to 50 Sv (regional deposition) - allows multiple administrations



Results – Aged & diluted SS

| | Total | Head | Thorax | TB | P | t½ TB |
|-----------------|----------------|--------------|----------------|---------------|---------------|---------------|
| 6x1000 Nasal | 61±10 | 6±2 | 55±11 | 14±5 | 41±7 | 8.3±3.3 |
| LUDEP | 33 | 0.7 | 32.2 | 6.5 | 25.7 | |
| 6x1000 Oral | 43.1 ± 16.2 | 2.8 ± 1.2 | 40.5 ± 12.2 | 10.2 ± 3.8 | 30.3 ± 9.4 | 8.4 ± 2.2 |
| LUDEP | 33 | 0.6 | 32.4 | 6.6 | 25.7 | |
| 12x500 Oral | 23±8 | 2±1 | 21±8 | 4±3 | 16±6 | 11.6 ± 2.8 |
| LUDEP | 20.5 | 0.6 | 19.9 | 6.0 | 14.0 | |

Aged SS data : deposition comparison



- Oral 6 x 1000 : $43.1 \pm 16.2\%$
(Strong et al, Rad. Prot. Dos. 54 47-56 (1994))
- Oro-nasal 8 x 1000_60 min_MMAD 140 nm 41 ± 14
(McAughey et al, Inhalation Toxicology 6 615-631 (1995))
- Oral 410 nm MMAD 11 ± 4
(Hiller et al, Prev. Med. 13 602-607 (1984))
- Nasal 200 nm CMD 56.0 ± 15.9
- Oral 200 nm CMD 48.7 ± 11.5
(Hofmann et al, J. Aerosol Med. 14 317-326 (2001))

Mainstream smoking parameters




| Marker | Male | Female |
|---------------------------|------------|------------|
| Puff Volume (ml) : 13 mg | 58 ± 20 | 48 + 10 |
| Puff Volume (ml) : 10 mg | 70 ± 21 | 55 ± 10 |
| Puff Duration (s) : 13 mg | 2.0 ± 0.7 | 2.1 ± 0.6 |
| Puff Duration (s) : 10 mg | 1.9 ± 0.5 | 1.9 ± 0.4 |
| Puff Flow (ml/s) : 13 mg | 29.0 ± 3.7 | 24.1 ± 4.7 |
| Puff Flow (ml/s) : 10 mg | 35.5 ± 5.5 | 28.8 ± 5.1 |
| Chest TPM (mg) : 13 mg | 13.9 ± 4.6 | 12.4 ± 3.8 |
| Chest TPM (mg) : 10 mg | 14.0 ± 3.9 | 12.0 ± 3.9 |
| Total TPM (mg) : 13 mg | 14.7 + 4.5 | 13.9 + 3.1 |
| Total TPM (mg) : 10 mg | 14.8 + 3.7 | 14.1 + 3.3 |

Results – MS smoking (Head:TB:P ratios)



| Marker | | Male | Female |
|------------------|---------|------------|-------------|
| Head (%) | 13 mg | 5.4 | 10.8 |
| | 10 mg | 5.4 | 14.9 |
| P/(P+TB) (%) | 13 mg | 66.6 ± 7.9 | 60.0 ± 8.6 |
| | 10 mg A | 65.9 ± 9.0 | 64.2 ± 12.1 |
| | 10 mg B | 64.5 ± 5.9 | 68.2 ± 8.4 |
| TB Half-life (h) | 13 mg | 1.4 ± 0.7 | 2.3 ± 1.6 |
| | 10 mg A | 2.2 ± 0.9 | 1.7 ± 1.0 |
| | 10 mg B | 1.8 ± 0.9 | 1.6 ± 0.7 |
| P Half-life (h) | 13 mg | 15.9 ± 1.6 | 24.5 ± 19.0 |
| | 10 mg A | 17.1 ± 2.6 | 18.0 ± 2.7 |
| | 10 mg B | 17.8 ± 2.2 | 17.4 ± 3.1 |

Retention curve, MPPD Dosimetry Model



Summary

- Low-dose radiotracers combined with a g-detection array have been used to determine regional deposition patterns of mainstream and aged & diluted sidestream smoke (ETS)
- Exhale capture for ETS has also yielded absolute retention data
- Retention is generally greater than model predictions
- The pattern of thoracic regional deposition of is such that most mass is delivered to the pulmonary region
 - 60 – 68% for MS
 - 75 – 76% for ETS
- However, highest mass per unit area will occur in TB region
- Deposition patterns are consistent with small (sub-micron) particle deposition

Acknowledgements



- Sponsors

- MS : Tobacco Products Research Trust
- ETS : Center for Indoor Air Research (^{212}Pb)
- ETS : Rothmans International Tobacco (UVPM, solanesol)

- Harwell Team

- Alec Black, John Pritchard, John McAughey, Denise Knight, Colin Dickens & John Strong